Tag: MAH

How MAHs Should Respond to Emerging Safety Concerns

How Marketing Authorization Holders Can Effectively Address Emerging Safety Concerns Key Takeaways Proactively monitor safety data to identify emerging safety concerns promptly. Engage in transparent communication with regulatory authorities and stakeholders. Implement a structured risk management plan that is adaptable to new information. Train your teams on the latest pharmacovigilance…

Marketing Authorisation Holder Responsibilities in Signal Management

Understanding the Role of Marketing Authorisation Holders in Signal Management Key Takeaways The Marketing Authorisation Holder (MAH) plays a crucial role in ensuring patient safety through effective signal management. Regular training and updates on regulatory changes are essential for maintaining compliance and readiness for inspections. Clear communication and collaboration between…

Additional Risk Minimisation Measures Explained for MAHs

Understanding Additional Risk Minimisation Measures for Marketing Authorisation Holders Key Takeaways Additional risk minimisation measures (aRMMs) are crucial for ensuring patient safety and effective communication of risks associated with specific medicinal products. Implementing aRMMs requires a tailored approach that considers the specific risk profile of the product and its target…

Additional Risk Minimisation Measures Explained for MAHs

Understanding Additional Risk Minimisation Measures for Marketing Authorisation Holders Key Takeaways Additional risk minimisation measures (aRMMs) are critical tools for managing the safety profile of medicinal products. Effective implementation of aRMMs requires thorough planning and continuous monitoring to ensure compliance with regulatory requirements. Regular communication with stakeholders, including regulatory authorities…